Thomas B. Kjeldsen - Publications

Predicting human half-life for insulin analogs: An inter-drug approach.

Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V

Published: April 05, 2024

Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec.

Journal: Nature communications

Published: January 31, 2024

Molecular engineering of insulin for recombinant expression in yeast.

Journal: Trends in biotechnology

Published: August 10, 2023

Derivatization with fatty acids in peptide and protein drug discovery.

Journal: Nature reviews. Drug discovery

Published: June 29, 2022

Molecular Engineering of Efficacious Mono-Valent Ultra-Long Acting Two-Chain Insulin-Fc Conjugates.

Journal: Journal of medicinal chemistry

Published: February 01, 2022

A Hundred Years of Insulin Innovation: When Science Meets Technology.

Journal: Diabetes

Published: August 21, 2021

Author Correction: Molecular engineering of safe and efficacious oral basal insulin.

Journal: Nature communications

Published: July 10, 2021

Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans.

Journal: Journal of medicinal chemistry

Published: May 04, 2021

Molecular and pharmacological characterization of insulin icodec: a new basal insulin analog designed for once-weekly dosing.

Journal: BMJ open diabetes research & care

Published: March 30, 2021

Commemorating insulin's centennial: engineering insulin pharmacology towards physiology.

Journal: Trends in pharmacological sciences

Published: March 11, 2021

Cell free protein synthesis versus yeast expression - A comparison using insulin as a model protein.

Journal: Protein expression and purification

Published: February 11, 2021

Engineering of Orally Available, Ultralong-Acting Insulin Analogues: Discovery of OI338 and OI320.

Journal: Journal of medicinal chemistry

Published: December 28, 2020